Acrigen Biosciences is an early-stage life science gene editing company based in Berkeley, California. We are building a pipeline of therapies to treat genetic disorders using our proprietary precision gene editing technology. Our technology utilizes novel CRISPR-Cas gene editors coupled with anti-CRISPR proteins to improve the precision, efficacy, and safety of genetic therapies. The company was co-founded in 2019 by Dr. Joseph Bondy-Denomy (Associate Professor at UCSF and discoverer of anti-CRISPR proteins) and Dr. David Rabuka (former Founder and CSO of Redwood Biosciences) with the mission of bringing precision genetic therapies to the clinic.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 1000 Atlantic Ave,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- acrigen.com
- HQ
- Alameda, California
Acrigen Biosciences Questions
Acrigen Biosciences's website is acrigen.com
Acrigen Biosciences's LinkedIn profile is https://www.linkedin.com/company/acrigen-biosciences
Acrigen Biosciences has
6 employees.
View email and phone details for 6
employees at Acrigen Biosciences.
Acrigen Biosciences's industry is
Biotechnology Research
Acrigen Biosciences's top competitors are
Scribe Therapeutics,
Caribou Biosciences,
Actym Therapeutics, Inc.,
Berkeley Yeast,
Metagenomi,
Omega Yeast,
Regel Therapeutics,
Acrobat Genomics,
Aeovian Pharmaceuticals,
Sardona Therapeutics.
Acrigen Biosciences's categories are Biotechnology Research
Acrigen Biosciences's founding year is 2019
